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Available online xxxxAim:Metalloproteinases inhibition by doxycycline reduces cardiac protein degradation at extracellular and intra-
cellular level in the experimental model ischemia/reperfusion injury. Since both extracellular cardiac matrix and
titin filaments inside the cardiomyocyte are responsible for themyocardial stiffness, we hypothesized that doxy-
cycline could favorably act on left ventricular (LV) filling pressures in patients after reperfused acute ST-elevation
myocardial infarction (STEMI).
Methods and results: Seventy-three of 110 patients of the TIPTOP trial underwent a 2D-Echo-Doppler on admis-
sion, and at pre-discharge and at 6-month after a primary PCI for STEMI and LV dysfunction. From admission to
pre-discharge, LV filling changed from a high filling pressure (HFP) to a normal filling pressure (NFP) pattern in
91% of the doxycycline-group, and in 67% of the control-group. Conversely, 1% of the doxycycline-group, and 37%
of the control-group changed the LV filling from NFP to HFP pattern. Overall, a pre-discharge HFP pattern was
present in 4 patients (11%) of the doxycycline-group and in 13 patients (36%) of the control-group (p =
0.025). The evaluation of metalloproteinases and their tissue inhibitors plasma concentrations provide possible
favorable action of doxycycline. On the multivariate analyses, troponine I peak (p = 0.026), doxycycline (p =
0.033), and on admission to pre-discharge LVEF changes (p = 0.044) were found to be associated with pre-
discharge HFP pattern. Independently of their baseline LV filling behavior, the 6-month remodeling was less in
patients with pre-discharge NFP pattern than in patients with HFP pattern.
Conclusions: In patients with STEMI and LV dysfunction doxycycline can favorablymodulate the LVfilling pattern
early after primary PCI.
© 2017 Elsevier B.V. All rights reserved.Keywords:
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Primary percutaneous coronary interventionDoppler echocardiography has provided a rapid, feasible, and simple
noninvasive method of assessing left ventricular (LV) filling in various
cardiac diseases in which diastolic abnormalities have been observed
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rly changes of left ventricular
7), http://dx.doi.org/10.1016/that the presence of echocardiographic indexes of elevated LV filling
pressures, as a marker of LV diastolic dysfunction, predicts a poor prog-
nosis early after acute myocardial infarction (AMI) [2], despite pharma-
cological [3] or mechanical reperfusion [4,5] and independently of
systolic function [2]. Thus, a major unresolved question is how to opti-
mally manage AMI patients having advanced LV diastolic dysfunction
[6].
For the first time in the clinical setting, the TIPTOP (Early Short-term
Doxycycline Therapy In Patients with Acute Myocardial Infarction and
Left Ventricular Dysfunction to Prevent TheOminous Progression to Ad-
verse Remodeling) trial [7] demonstrated that a timely, short-term
therapy with doxycycline is safe and able to induce a significant
decrease in LV dilation in patients successfully treated with primary
percutaneous coronary intervention (pPCI) for a first ST-elevation
AMI (STEMI) and LV dysfunction. Several pleiotropic properties offilling pattern after reperfused ST-elevationmyocardial infarction and
j.ijcard.2017.03.125
Table 1
Baseline clinical and procedural characteristics of the two study groups.
Doxycycline group Control group
(n.37) (n. 36)
Clinical findings
Age, years 72 [62–79] 71 [60–75]
Male sex, (%) 70 72
BAS, (kg/m2) 1,85 ± 0,2 1,82 ± 0,1
Heart rate, (b.p.m) 77 ± 16 79 ± 13
Systolic blood pressure, (mm Hg) 130 [110–150] 130 [111–150]
Diabetes, (%) 21 19
Dyslipidaemia, (%) 30 22
Hypertension, (%) 54 39
Symptoms to door time, (min) 145 [89–229] 137 [90–315]
Pro-BNP, (pg/mL) 575 [173–2195] 648 [175–3177]
Troponine I peak, (μg/ml) 196 ± 177 277 ± 192
Echo-color-Doppler findings
E-wave peak, (cm/s) 64 ± 20 64 ± 19
A-wave peak, (cm/s) 81 ± 18 78 ± 21
EA ratio 0,8 ± 0,5 0,9 ± 0,4
DT, (ms) 194 ± 60 191 ± 52
Septal E′-wave peak, (cm/s) 7 ± 3 7 ± 2
Vp, (cm/s) 30 [25–42] 33 [21–48]
High filling pressures pattern, (%) 30 17
LVEDVi, (mL/m2) 47 [41–57] 47 [40–61]
LVESVi, (mL/m2) 31 [24–35] 31 [23–37]
LVEF, (%) 39 [32–44] 37 [33–43]
Angiographic and procedural findings
Left anterior descending artery, (%) 94 89
IRA TIMI flow grade b2 pre-PCI, (%) 68 67
Multivessel disease, (%) 44 49
IRA stenting, (%) 100 100
Number of stents 1,3 ± 0,6 1,4 ± 0,6
Stent length, (mm) 20 [16–31] 20 [16–27]
IRA TIMI flow grade 3 post-PCI, (%) 100 100
Procedural time, (min) 27 [20–41] 28 [21–35]
Pharmacological therapy
Aspirin, (%) 94 98
Thienopyridine, (%) 100 100
Abciximab, (%) 87 95
Statin, (%) 100 100
Beta-adrenergic blocker, (%) 94 83
ACE inhibitor/ARB antagonist, (%) 75 86
Mineral-receptor-antagonist, (%) 19 28
Loop diuretic, (%) 40 47
BAS denotes body surface area, BNP, brain natriuretic peptide, E-wave, peak early ventric-
ular filling velocity, A-wave, peak late ventricular filling velocity, DT, deceleration time of
early filling velocity, E′ early diastolic peak velocity on the septal side of themitral annulus,
Vp,flowpropagation velocity during earlyfilling, LVEDVI, left ventricular end diastolic vol-
ume index, LVESVi, left ventricular end systolic volume index, LVEF, left ventricular ejec-
tion fraction, IRA, infarct-related artery, TIMI, thrombolysis in myocardial infarction,
ACE, angiotensin-converting-enzyme, ARB, angiotensin II receptor blockers. Values are
expressed as mean ± SD, or median [IQ range] or number (%).
2 G. Cerisano et al. / International Journal of Cardiology xxx (2017) xxx–xxxdoxycycline [8] mainly related to its ability to act as a matrix metallo-
proteinases (MMPs) inhibitor at the level of extracellular collagen ma-
trix (ECM) [9] could explain this favorable anti-remodeling effect
observed in the experimental [10,11] and clinical [12] setting. Metallo-
proteinases activation can also occur intracellularly in heart subjected
to ischemia/reperfusion (I/R), and it is responsible for the degradation
of sarcomeric proteins including titin [13–15], thus contributing to
cardiomyocytes injury under oxidative stress. Accordingly, MMPs inhi-
bition by doxycycline prevents acute stunning in isolated rat-hearts
subjected to I/R injury [13,14] andmimics theMMP-2 inhibition and in-
farct size reduction found with ischemic post-conditioning [16]. Since
both ECM and titin filaments inside the cardiomyocyte are two impor-
tant components responsible for the myocardial stiffness, it is possible
to hypothesize that doxycycline, through its MMPs-inhibitor action,
has a favorable effect on diastolic LV filling.
Thus, we set out to analyze the time course of changes in the LV fill-
ing pattern during the acute stage of STEMI treated with doxycycline in
the TIPTOP trial.
1. Methods
1.1. Study design, patients and procedures
The TIPTOP study design has been already descripted in detail [7]. In brief, TIPTOP trial
is a prospective, phase-2, single-centre, randomized, open-label controlled trial in which
110 patients older than 18 years with acute STEMI and LV ejection fraction (LVEF) b 40%
were randomly assigned in a 1:1 ratio to receive doxycycline or standard care. All patients
were treated with primary PCI, including stenting of the infarct-related artery (IRA), and
received medical therapy for STEMI and LV dysfunction in accordance with standard
and recommended practice. Doxycycline (Bassado; Pfizer Italia s.r.l.) was administered
at 100mg oral dose immediately after primary PCI and then every 12 h for 7 days. The an-
timicrobial dose we used ensures plasma levels of doxycycline similar to those obtained
with higher doses used in the experimentalmodelwhere thedoxycyclinehas beenproved
effective in inhibiting MMPs and preventing abdominal aortic aneurysm [17] and post-
infarction LV remodeling [10,11]. The pre-defined primary endpoint of the TIPTOP trial
was the percent change from baseline to 6 months in echocardiographic LV end-
diastolic volume index (LVEDVi). Thus, two-dimensional and Doppler echocardiographic
examinations (2D-Echo-Doppler) at baseline (immediately after primary PCI) and at
6monthswere performed. DICOM standardized imageswere recorded and stored on dig-
ital media, and sent to an independent, blinded, off-site core laboratory for analysis. The
study plan also included: i) 99mTc-sestamibi-gated single-photon emission computed to-
mography (SPECT) to evaluate the final infarct size and severity at 6-month follow-up
and ii) a coronary angiography at 6months for the evaluation of IRA patency. Local ethical
committee approved the study protocol, and informedwritten consentwas obtained from
the subjects. Doxycycline was provided directly from the local hospital, and the manufac-
turer had no role in the study.
For the present study we analyzed 73 of 110 patients of the TIPTOP trial, specifically
those for which a 2D Echo-Doppler assessment including diastolic function was available
also at pre-discharge (average 6 ± 3 days), a not pre-specified time-point of echocardio-
graphic evaluation of the TIPTOP [7], as well as at baseline and six-month follow-up. Pa-
tients in the present sub-study had similar clinical characteristics to those included in
the main trial (see Appendix A of the Supplementary Data). Both the main trial and the
present sub-study were conducted in accordance with the Declaration of Helsinki.
1.2. Echocardiographic analyses
Two-D Echo-Doppler studies were performed with a commercially available imaging
systems (Philips IE-33, Amsterdam, The Netherlands), and the following measurements
were obtained according to established criteria [1,18]: i) LV volumes and ejection fraction,
ii) peak of early (E) and late (A) transmitral velocities and E-wave deceleration time (DT),
iii) peak of early (E′) septal mitral annulus velocities and iiii) LV flow propagation velocity
during early filling (Vp). According to the protocol of the main study [7], LV dysfunction
was defined as an LVEF b40%, as calculated by the on-site operator at the first echo exam-
ination in the coronary care unit immediately after primary PCI. Consistent with the cur-
rent guidelines [1] on patients with LV systolic dysfunction (such as our patients), we
defined a high filling pressure (HFP) pattern an E/A ratio ≥2, and a normal filling pressure
(NFP) pattern an E/A ratio ≤0,8 and E b 50 cm/s, respectively. For patients that fall in be-
tween, HFP was confirmed in presence of an E/E′ ratio N15 [19] or an E/Vp ratio ≥2,5 [20].
1.3. Statistical analyses
Discrete data were summarized as frequencies, whereas continuous data were sum-
marized as mean ± SD or median and interquartile range, when appropriate. Differences
in baseline characteristics between the two study groups were analyzed using the x2 test
or Fisher's exact test for categorical variables, and the unpaired and paired, 2-tailed
Student's t-test or Mann-Whitney test for continuous variables. Univariable andPlease cite this article as: G. Cerisano, et al., Early changes of left ventricular
doxycycline therapy: Ins..., Int J Cardiol (2017), http://dx.doi.org/10.1016/multivariable logistic regression analyses were performed to evaluate the independent con-
tributions of pre-discharge HFP pattern. Over that baseline clinical and therapeutic variables,
the changes from baseline to pre-discharge of LVEDVi, LVEF and pro-BNP release at pre-
discharge were also tested in view of the possible interaction between the LV filling pattern
and the concomitant LV remodeling process. The variables tested in the univariate model
were listed in Table 2. For the significant variables on univariate analysis (p-value b0.05),
multicollinearity was assessed using collinearity diagnostics. The variance inflation factors
showed no significant collinearity among these covariates (b2.0). Variables with a p-value
b0.05 at univariable model, were entered into the multivariable model. All tests were two-
sided, and a p-value b0.05 was considered statistically significant. Analyses were performed
with SPSS software, version 19 (IBM Corp, Somers, NY).2. Results
2.1. Study patients
The baseline clinical, echocardiographic, angiographic/procedural
and therapeutic characteristics, of the two study groups are shown in
Table 1. There were no significant differences between the two studyfilling pattern after reperfused ST-elevationmyocardial infarction and
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was a greater incidence of hypertension, HFP pattern, left anterior de-
scending (LAD) disease, and lower troponin I peak values.
2.2. Left ventricular filling pattern on admission and relationship with pro-
Brian natriuretic peptide
The echo-Doppler mitral inflow velocities recorded on admission
allowed to classify 19 patients as NFP pattern, and 2 patients as HFP pat-
tern, respectively. For the remaining 52 patients with inconclusive mi-
tral inflow velocities, the further assessment of E/E′ or E/Vp ratio
allowed to reclassify 37 patients in the NFP group and 15 in the HFP
group, respectively. The time course of plasma pro-brain natriuretic
peptide (BNP) release was available in 82% of these patients. Of note,
the patients in which E/E′ and E/Vp met the cutoff threshold for HFP
showed higher values of baseline pro- BNP than their counterparts
(2870 pg/mL± 2833 vs. 1105 pg/mL± 1505, p=0.01) despite similar
values of baseline LVEF (38%± 7 vs. 39%± 7, p=0,82), and troponin I
peak (263 μg/L ± 209 vs. 247 μg/L ± 188, p= 0.94), respectively.
2.3. Early changes in LV filling pattern, volumes and ejection fraction in the
two study groups
Serial changes in LV filling pattern from baseline to pre-discharge in
the two study groups are detailed in Fig. 1. From baseline to pre-
discharge, the LV filling changed from HFP to NFP pattern in 91% of pa-
tients in the doxycycline-group, and in 67% of those in the control-
group, respectively. Conversely, LV filling changed fromNFP to HFP pat-
tern in 11% of patients in the doxycycline-group, and in 37% of those in
the control-group, respectively. Overall, a pre-discharge HFP pattern
was present in 11% of patients in the doxycycline group and in 36% of
patients in the control group, respectively (p= 0.025).
Themodifications in LVfilling patternwere accompanied by a signif-
icant increase in LV volumes in the control-group compared to the
doxycycline-group (Δ LVEDVi: 10 ml/m2 [from −1 to 15 ml/m2] vs.
1 ml/m2 [from−4 to 9 ml/m2], p = 0.014; Δ LVESVi: 4 ml/m2 [fromNFP n. 26
HFP n.11
NFP n.30
HFP n.6
BASELINE 
L.V. FILLING  PATTERN
DOXYCYC
CONTR
n.23
n.1
n.19
n.2
Fig. 1. Early changes in LV filling pattern in the two study groups. From baseline to pre-d
LV filling pattern compared to control-group. So that, a pre-discharge HFP was present
group, respectively (36% vs. 11%, p = 0.025).
Please cite this article as: G. Cerisano, et al., Early changes of left ventricular
doxycycline therapy: Ins..., Int J Cardiol (2017), http://dx.doi.org/10.1016/−2 to 12 ml/m2] vs. 0,4 ml/m2 [from−4 to 6 ml/m2], p= 0.043). The
LVEF increased in the doxycycline-group while decreased in the
control-group. This difference was not significant, however (3% [from
−3 to 9%] vs.−1% [from−6 to 7%], p= 0.183).
2.4. Independent predictors of pre-discharge high filling pressure pattern
The univariate and multivariate regression analyses were per-
formed to identify independent predictors of pre-discharge HFP pat-
tern (Table 2). In addition to the baseline clinical, echocardiographic,
angiographic, procedural, and therapeutic characteristics, we evalu-
ated the peak of troponine I, as estimate of initial infarct size, and
echocardiographic (LV volumes and LVEF changes from baseline to
pre-discharge) and neurohormonal (pre-discharge plasma pro-BNP
values) indexes which reflect a concomitant early LV remodeling
process. The significant variables in the univariate analysis were en-
tered in the multivariate model. The troponine I peak values (p =
0.026), doxycycline therapy (p = 0.033), and baseline to pre-
discharge LVEF changes (p=0.044) were found to be independently
associated with pre-discharge HFP pattern.
2.5. Relationship between pre-discharge LV filling pressure pattern and 6-
month echocardiographic findings
One patient in the control group with pre-discharge HFP died for
heart failure in thefirstmonth after indexmyocardial infarction, and an-
other patient refused to complete the echocardiographic follow-up.
Thus the 6-month echocardiographic follow-up was available in 71 of
73 patients.
From baseline to 6 months, LV volumes decreased, and LVEF in-
creased in patients with pre-discharge NFP pattern (n=56) compared
to their counterpart (n=17), respectively (Δ LVEDVi: 0.5 ml/m2 [from
−5 to 9 ml/m2] vs.7 ml/m2 [from −17 to 14 ml/m2], p = 0.08; Δ
LVESVi: −4 ml/m2 [from −11 to 1 ml/m2] vs.1.5 ml/m2 [from −7.5
to 12 ml/m2], p = 0.03; Δ LVEF: 11% [from 5 to 19%] vs. 4% [from−4
to 12%], p = 0.04), (Fig. 2). Patients with pre-discharge NFP patternNFP n.33 (89%)
HFP n.4 (11%)
NFP n.23 (64%)
HFP n.13 (36%)
PRE-DISCHARGE 
L.V. FILLING PATTERN
LINE
OL
n.11 (37%)
n. 4 (67%)
n.3 (11%)
n.10 (91%)
ischarge, in the doxycycline-group was observed a more favorable modification of
in a significantly higher percentage of patients of control-group than doxycycline-
filling pattern after reperfused ST-elevationmyocardial infarction and
j.ijcard.2017.03.125
Table 2
Independent predictors of high filling pressure at pre-discharge.
Univariate logistic regression analysis Multivariate logistic regression analysis
Baseline clinical findings B Exp(B) 95% CI p B Exp(B) 95% CI p
Age, years 0,04 1,04 0,989–1104 0.114
Sex male, (%) −1,42 2,42 0,077–0,763 0.015 −3.966 0,02 0,000–3318 0.132
BSA, (kg/m2) −5.01 0,01 0,000–0275 0.008 −1953 0,142 0,000–4434 0.712
Heart rate, (bpm) 0,00 1,00 0,968–1041 0.852
Systolic blood pressure, (mm Hg) 0,00 1,00 0,980–1016 0.832
Diabetes, (%) −0.23 1,26 0,363–4619 0.729
Dyslipidaemia, (%) −1.17 0,84 0,237–2985 0.789
Hypertension, (%) −0.29 0,75 0,251–2256 0.611
Total ischemic time, (min) 0,002 1002 0,999–1005 0.193
Baseline echocardiographic findings
Baseline LVEDVi, (mL/m2) −0.02 0,98 0,937–1029 0.445
Baseline LVESVi, (mL/m2) −0.02 0,98 0,919–1036 0.423
Baseline LVEF, (%) 0,00 1,00 0,924–1091 0.925
Angiographic and procedural findings
IRA TIMI flow grade b2 pre-PCI, (%) −1,03 0,36 0,092–1390 0.138
Multivessel disease, (%) −0.02 0,98 0,478–1995 0.948
Stent length, (mm) −0.03 0,97 0,919–1030 0.347
Procedural time, (min) 0,02 1,03 0,997–1054 0.087
Pharmacological therapy
Abciximab, (%) −0.86 0,43 0,065–2779 0.371
Beta-adrenergic blocker, (%) −0.25 0,78 0,182–3300 0.735
ACE inhibitor/ARB antagonist, (%) −1.55 4,73 1282–17,44 0.023 0,542 1,72 0,064–46,19 0.747
Mineral-receptor-antagonist, (%) 1,17 3,22 0,986–10,515 0.053
Loop diuretics, (%) 0,48 1,61 0,542–4806 0.390
Doxycycline, (%) −1.54 0,21 0,062–0,742 0.015 −5113 0,01 0,000–0,666 0.033
Enzymatic infarct size
Troponine I peak, (μg/L) 0,01 1,01 1002–1008 0.000 0,009 1,01 1001–1017 0.026
Pre-discharge findings
Pre-discharge pro-BNP, (pg/mL) 0,00 1,00 1000–1001 0.004 0,001 1,00 1000–1002 0.120
Baseline-pre-discharge LVEDVi changes, (mm) 0,06 1059 1000–1122 0.051 −0.092 0,912 0,741–1123 0.367
Baseline-pre-discharge LVEF changes, (mm) −0.08 0,92 0,885–0,995 0.036 −0.255 0,775 0,604–0,994 0.044
Abbreviations as in Table 1.
4 G. Cerisano et al. / International Journal of Cardiology xxx (2017) xxx–xxxalso showed a lower, but not significant prevalence of 6 months HFP
pattern compared to patients with pre-discharge HFP pattern (11% vs.
25%, p= 0.217).
Remarkably, the favorable remodeling that we observed in patients
with pre-discharge NFP occurred regardless of the LV filling pattern
present at baseline assessment. Indeed, the 14 patients with LV filling
pattern changes from HFP to NFP from baseline to pre-discharge
showed a similar 6-month evolutionary changes in LV volumes in com-
parison to the 42 patients with NFP pattern at baseline aswell as at pre-
discharge assessment (Δ LVEDVi:−3ml/m2 [from−12 to 8ml/m2] vs.
1 ml/m2 [from−4 to 9 ml/m2], p = 0.10; Δ LVESVi:−7 ml/m2 [from
−15 to 1 ml/m2] vs. −3 ml/m2 [from −10 to 1 ml/m2], p = 0.24).p = 0.08 p = 
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Fig. 2. Relationship between pre-discharge LV filling pressure pattern and 6-month echocardio
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[from 3 to 17%] vs. 11% [from 5 to 19%], p= 0.62).
2.6. Relationship between plasmaMMPs/TIMPs, therapy and LV filling pres-
sure pattern
The baseline plasmaMMPs/TIMPs were not different between the two
treatment groups (see Appendix B of the Supplementary Data). However,
several significant differences between the 2 study groups were found, ac-
cording to the baseline echocardiographic pattern of LV filling pressures
(see Appendix C of the Supplementary Data). Nominally, control-patients
in HFP-pattern-group showed a significant increase in MMP-7/TIMP-3 at0.03 p = 0.04
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and -3 at 6month follow-up, respectively. On the contrary, 1-monthMMP-
9/TIMP-1 and -4 ratios, and MMP-8/TIMP-4 ratio significantly increased in
doxycycline-group than control-group.
3. Discussion
The unique and significantfindings from this study are twofold. First,
a short-time treatment with doxycycline, initiated early after mechani-
cal reperfusion in patients with STEMI and LV dysfunction, is associated
with a significant improvement in LV filling pattern on echocardio-
graphic assessment from hospital admission to pre-discharge. Impor-
tantly, this relationship was independent of the enzymatic infarct size,
and concomitant LV remodeling process. Second, compared to patients
with pre-discharge HFP, patients with pre-discharge NFP pattern
showed less 6-month LV remodeling and, importantly, this occurred re-
gardless of baseline LV filling pattern.
The ECM plays a major role in post-myocardial infarct remodeling
[21]. Increased MMPs activation (such as MMP-1, -2, -3, -8, -9 and
-14) is a well-accepted pathway leading to early ECM damage and LV
remodeling [21]. The inhibition of MMPs by synthetic inhibitors has
been shown to be able to reduce post-infarction adverse remodeling
in animals [22–25], but not in humans [26].
For thefirst time, the TIPTOP study [7] has demonstrated that a time-
ly short-term therapy with doxycycline in patients with acute STEMI
and LV dysfunction significantly reduces the adverse LV remodeling
for comparable definite infarct size. This effect may be due to an up-
regulation doxycycline-related of tissue inhibitor of MMP-2 in the first
days post myocardial infarction [12]. Moreover, doxycycline possesses
cytoprotective effects that are likely secondary to its capacity to act as
anti-inflammatory, anti-apoptotic, reactive oxygen species scavenger,
as well as MMPs inhibitor [10].
The current analysis of the TIPTOP study opens new perspectives on
mechanisms through which doxycycline may determine its favorable
action in STEMI patients. In fact, doxycycline therapy was associated
with a favorable dynamic behavior of the LV filling during the hospital
stage of acute STEMI, resulting in a significantly lower percentage of
pre-discharge HFP compared to the control group.
There is no doubt that pharmacological MMP inhibition can favor-
ably alter the course of post-myocardial infarction remodeling in term
of LV volumes and function [27]. For example, in the experimental
models of AMI in the rat [10] and mice [28], the treatment with broad
spectrum inhibitors ofMMPs (PD-166793) and doxycycline, respective-
ly, significantly decreased LV dilation 14 days after index infarction, and
yielded parallel reduction of LV end-diastolic pressure.
Because of its design, this study was unable to demonstrate any
cause-effect relationships, but only correlations, which, however,
allow for some interesting hypotheses. First, in control-patients with
baseline HFP pattern, the early time-course of MMPs/TIMPs profile
was dominated by sustained higher plasma MMP-7/TIMPs ratios than
in doxycycline-patients. In adult sheep model of myocardial infarction,
MMP-7 deficiency has been related to an improvement of remodeling
process after localized delivery of biocomposite materials into infarcted
myocardium [29]. Then again, MMP-7 has a large proteolytic portfolio
[30] that can modify ECM composition and, consequently, LV architec-
ture, and systolic and diastolic function. Our results suggest this possi-
bility, at least in the clinical setting of STEMI and elevated LV filling
pressures. Second, at 1-month follow-up doxycycline-patients with
HFP pattern showed higher MMP9/TIMP-1 and -4 and MMP-8/TIMP-4
ratios than control-patients with HFP pattern. Although an early in-
crease of MMP-9 and -8 has been related to adverse LV remodeling [9], in
a later phase ofmyocardial infarction this same proteolytic activity canme-
diatewoundhealing [31] andpreserve LV systolic function [32]. Consistent-
ly, an early short-term MMPs inhibition after experimental myocardial
infarction confers a beneficial effect, while a prolonged MMPs inhibition
is associated with an adverse LV remodeling [33]. Third, the MMPs/TIMPsPlease cite this article as: G. Cerisano, et al., Early changes of left ventricular
doxycycline therapy: Ins..., Int J Cardiol (2017), http://dx.doi.org/10.1016/ratios changes we observed between the two study-groups, only occurred
in patients with baseline HFP pattern. Likely, in the low-risk patients with
acute STEMI, such as thosewithNFP pattern, the powerful salvaging capac-
ity of primary PCI with routine use of modern anti-thrombotic drugs over-
whelms the benefits of additional pharmacological cardioprotective
strategies, which could otherwise show benefit in patients known to be
at higher risk, such as those with HFP pattern.
However, it is interesting to note that in the present study doxycy-
cline was directly associated to a pre-discharge NFP pattern also after
controlling for indexes of early concurrent LV remodeling process,
namely the LVEDVi and LVEF. Thus, the question arises whether other
actions different than ECM modulation can contribute to the relation-
ship between doxycycline and diastolic function early after STEMI. Ali
and Coll [15] showed both in rat and human myocardium that MMP-2
colocalizes with titin, and that cleavage of titin in rat hearts subjected
to I/R injury was prevented by a selective MMP inhibitor (ONO-4817).
Thus, this study highlights an interesting link between the two compo-
nents responsible for myocardial stiffness: the ECM (also known to be
degraded byMMPs includingMMP-2) and titin filaments inside the car-
diomyocyte. Metalloproteinase-2 is responsible also for the degradation
of troponin I [13] andmyosin light chain [14] after I/R injury, and doxy-
cycline has been shown to inhibit both [13,14]. In our study, we did not
observe significant differences in MMP-2 plasma levels according to doxy-
cycline therapy. However, sincewemeasured the plasmaMMP concentra-
tion, we cannot exclude that doxycycline may have modulated post-
translationMMP activity [34]. Anyway, the protective effect of doxycycline
on titin is currently only an intriguing and plausible hypothesis.
In the present study we have observed a pre-discharge HFP pattern in
23% of patients. This finding is in agreement with previous reports in
which HFP, as assessed by Doppler transmitral flow profile and/or by a
short DT, ranged from 13 to 26% in non-selected patients with AMI treated
with medical therapy [35–37], and occurred in≈20% of 3396 patients in-
cluded in the most recent MeRGE study [2]. Importantly, in the MeRGE
study itwas associatedwith a3-fold increase in risk of death,with a consid-
erably greater power than any previous study [2]. Our patients with pre-
discharge NFP have a better outcome at 6-month follow-up in terms of
LV remodeling compared to patients with HFP. Also this result is in agree-
mentwith previous reports [3–5], and likely provide the critical linkage be-
tween HFP and poor clinical outcome after AMI. Since the favorable
outcome associated with the pre-discharge NFP pattern occurs regardless
of baseline LV filling pattern, the pre-discharge period appear a good
time-point for an effective assessment of diastolic function in survivors of
the acute phase of a myocardial infarction.
The present analysis is subject to several limitations. The first is the lack
of simultaneous hemodynamic measurement obtained with Eco-Doppler
examination. The non-invasive evaluation of LVfillingmight be problemat-
ic to differentiate normal from pseudonormal transmitral velocity pattern.
However, both E’ and Vp have been shown to be reliable in detecting a
pseudonormal LV filling pattern, especially in patients with LV systolic dys-
function such as our patients. An E/E′ ratio N15 aswell as an E/Vp ratio ≥2.5
not only predict highfilling pressureswith reasonable accuracy [19,20], but
they have also shown to be highly predictive of a poor prognosis after AMI
[38,39]. A further support of the reliability of these indexes in classifying the
proper LVfilling pattern arises from the fact that our patientswith E/E′ ratio
N15or E/Vp ≥2.5 had significantly higher values of pro-BNP respect to their
counterparts [40,41], despite similar values of enzymatic infarct size and LV
systolic function. Second, given the small sample size, LVfilling patternwas
evaluated using a binary approach, namely NFP/HFP. Therefore, HFP-group
comprises patients with Echo-Doppler findings indicative of both
pseudonormal and restrictive filling pattern. However, this factmight be ir-
relevant fromaclinical point of viewsincebothpatternshave shownanun-
favorable prognosis post AMI than patient without echo-Doppler findings
of HFP [2]. Third, we only analyzed selectedMMPs and therefore our anal-
ysis may have oversimplified the complex interplay of MMPs and TIMPs
[42]. Finally, this is a post hoc analysis of a small randomized trial and the
results can be considered only hypothesis generating.filling pattern after reperfused ST-elevationmyocardial infarction and
j.ijcard.2017.03.125
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remodeling must be confirmed by double-blind study via MRI and
Echo-Doppler modalities. Obviously, the impact of doxycycline on
long-term clinical outcomes should be further assessed in the future
with more highly powered studies.
4. Conclusions
In patients treated by primary PCI for a first STEMI with LV dysfunc-
tion, timely, short-term therapy with doxycycline can favorably
modulate LV diastolic filling pattern during the early stage of index
myocardial infarction. This may be one of the mechanisms by which
doxycycline has been shown to have a favorable effect in addition to
standard-of-care therapy for STEMI. To date, a major unresolved ques-
tion is how to manage optimally patients with abnormal LV filling.
Doxycycline can be an exciting opportunity.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcard.2017.03.125.
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